Endogenous opioids and chronic pain intensity: Interactions with level of disability

Clinical Journal of Pain

Volumn 20, Issue 5, 2004, Pages 283-292

  Bruehl, Stephen ^a,b   Chung, Ok Yung ^a   Ward, Pamela ^a   Johnson, Benjamin ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute pain; Chronic pain; Disability; Dysfunction; Endogenous opioids

Indexed keywords

NALOXONE; OPIATE;

ADULT; ANALGESIA; ANTINOCICEPTION; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISABILITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; NOCICEPTION; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSORY STIMULATION; TASK PERFORMANCE; UPREGULATION;

ADULT; BLOOD PRESSURE; CHRONIC DISEASE; CROSS-OVER STUDIES; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; PAIN MEASUREMENT; PAIN THRESHOLD; PERSONALITY ASSESSMENT;

EID: 4143062127     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002508-200409000-00002     Document Type: Article

References (61)

1. Bruehl S, McCubbin JA, Harden RN. Theoretical review: altered pain regulatory systems in chronic pain. Neurosci Biobehav Rev. 1999;23:877-890.
2. Fillingim RB, Maixner W, Kincaid S, et al. Pain sensitivity in patients with temporomandibular disorders: relationship to clinical and psychosocial factors. Clin J Pain. 1996;12:260-269.
3. Gibson SJ, Littlejohn GO, Gorman GG, et al. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain. 1994;58:185-193.
4. Langemark M, Jensen K, Jensen TS, et al. Pressure pain thresholds and thermal nociceptive thresholds in chronic tension-type headache. Pain. 1989;38:203-210.
5. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997;13:189-196.
6. Lautenbacher S, Rollman GB, McCain GA. Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain. 1994; 59:45-53.
7. Maixner W, Sigurdsson A, Fillingim RB, et al. Regulation of acute and chronic orofacial pain. In: Fricton, JR, Dubner R, eds. Orofacial Pain and Temporomandibular Disorders. New York: Raven Press; 1995.
8. Woolf CJ, Doubell TP. The pathology of chronic pain-increased sensitivity to low-threshold Aß-fibre inputs. Curr Opin Neurobio. 1997;4:525-534.
9. Granges G, Littlejohn G. Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum. 1993;36:642-646.
10. Vatine JJ, Tsenter J, Nirel R. Experimental pressure pain in patients with complex regional pain syndrome type 1 (reflex sympathetic dystrophy). Am J Phys Med Rehabil. 1998;77:382-387.
11. Kleinbohl D, Holzl R, Moltner A, et al. Psychophysical measures of sensitization to tonic heat discriminate chronic pain patients. Pain. 1999;81: 35-43.
12. Svensson P, List T, Hector G. Analysis of stimulus-evoked pain in patients with myofascial temporomandibular pain disorders. Pain. 2001;92: 399-409.
13. Boureau F, Luu M, Doubrere JF. Study of experimental pain measures and nociceptive reflex in chronic pain patients and normal subjects. Pain. 1991;44:131-138.
14. Peters ML, Schmidt AJM, Van den Hout MA, et al. Chronic back pain, acute postoperative pain, and the activation of diffuse noxious inhibitory controls (DNIC). Pain. 1992;50:177-187.
15. Edwards RR, Doleys DM, Fillingim RB, et al. Ethnic differences in pain tolerance: clinical implications in a chronic pain population. Psychosom Med. 2001;63:316-323.
16. Buchsbaum MD, Davis GC, Bunney WE. Naloxone alters pain perception and somatosensory evoked potentials in normal subjects. Nature. 1977; 270:620-622.
17. Frid M, Singer G, Oei T, et al. Reactions to ischemic pain: interactions between individual, situational, and naloxone effects. Psychopharm. 1981;73:116-119.
18. Gracely RH, Dubner R, Wolskee PJ, et al. Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature. 1983;306:264-265.
19. Pickar D, Cohen MR, Naber D, et al. Clinical studies of the endogenous opioid system. Biol Psychiatry. 1982;17:1243-1276.
20. Szyfelbein SK, Osgood PF, Carr DB. The assessment of pain and plasma beta-endorphin immunoreactivity in burned children. Pain. 1985;22:173-182.
21. Almay B, Johansson F, Von Knorring L, et al. Endorphins in chronic pain. I. Differences in CSF endorphin levels between organic and psychogenic pain syndromes. Pain. 1978;5:153-162.
22. Denko CW, Aponte J, Gabriel P, et al. Serum B-endorphin in rheumatic disorders. J Rheum. 1982;9:827-833.
23. Fukui T, Hameroff SR, Gandolfi AJ. Alpha-1-acid glycoprotein and beta-endorphin alterations in chronic pain patients. Anesthesiology. 1984;60: 494-496.
24. Johansson F, Almay BGL, Von Knorring L, et al. Personality traits in chronic pain patients related to endorphin levels in cerebrospinal fluid. Psychiatry Res. 1979;1:231-239.
25. Lipman JJ, Miller BE, Mays KS, et al. Peak B endorphin concentration in cerebrospinal fluid: reduced in chronic pain patients and increased during the placebo response. Psychopharmacology (Berl). 1990;102:112-116.
26. Puig MM, Laorden ML, Miralles FS, et al. Endorphin levels in cerebrospinal fluid of patients with postoperative and chronic pain. Anesthesiology. 1982;57:1-4.
27. Simonnet G, Taquet H, Floras P, et al. Simultaneous determination of radio-immunoassayable methionine-enkephalin and radioreceptor-active opiate peptides in CSF of chronic pain suffering and non-suffering patients. Neuropeptides. 1986;7:229-240.
28. Epping-Jordan JE, Wahlgren DR, Williams RA, et al. Transition to chronic pain in men with low back pain: predictive relationships among pain intensity, disability, and depressive symptoms. Health Psychol. 1998;17:421-427.
29. Bruehl S, Burns JW, Chung OY, et al. Anger and pain sensitivity in chronic low back pain patients and pain-free controls: the role of endogenous opioids. Pain. 2002;99:223-233.
30. Bruehl S, Chung OY, Ward P, et al. The relationship between resting blood pressure and acute pain sensitivity in healthy normotensives and chronic back pain sufferers: the effects of opioid blockade. Pain. 2002;100:191-201.
31. Tait RC, Pollard CA, Margolis RB, et al. The Pain Disability Index: psychometric and validity data. Arch Phys Med Rebabil. 1987;68: 438-441.
32. Chibnall JT, Tait RC. The Pain Disability Index: factor structure and normative data. Arch Phys Med Rehab. 1994;75:1082-1086.
33. Tait RC, Chibnall JT, Krause S. The Pain Disability Index: psychometric properties. Pain. 1990;40:171-182.
34. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiat. 1961;4:561-571.
35. Spielberger CD, Johnson EH, Russell SF, et al. The experience and expression of anger: construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, eds. Anger and Hostility in Cardiovascular and Behavioral Disorders. Washington, DC: Hemisphere Publishing Corp. 1985:5-30.
36. Spielberger CD, Jacobs G, Russell S, et al. Assessment of anger: The State-Trait Anger Scale. In: Butcher JN, Spielberger CD, eds. Advances in Personality Assessment. Vol 2. Hillsdale, NJ: LEA; 1983:161-189.
37. Lewis J, Mansour A, Khachaturian H, et al. Opioids and pain regulation. Pain Headache. 1987;9:129-159.
38. Forgione AG, Barber TX. A strain gauge pain stimulator. Psychophys. 1971;8:102-106.
39. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk, DC, Melzack, R, eds. Handbook of Pain Assessment. New York: Guilford Press; 1992:135-151.
40. Melzack R. The short form of the McGill Pain Questionnaire. Pain. 1987; 30:191-197.
41. Maurset A, Skoglund LA, Hustveit O, et al. A new version of the ischemic tourniquet pain test. Meth Find Exp Clin Pharmacol. 1992;13:643-647.
42. Wright KD, Asmundson GJG, McCreary DR. Factorial validity of the short-form McGill pain questionnaire (SF-MPQ). Eur J Pain. 2001;5: 279-284.
43. Kolaric S, Makulska-Nowak HE, et al. Paradoxical effects of intracerebroventricular low-dose opioid antagonists in SHR with chronic pain. Life Scien. 1999;65:395-402.
44. Foo H, Westbrook RF. Naloxone-induced hypoalgesia: evidence from the formalin test. Pharmacol Biochem Behav. 1993;45:501-505.
45. Crain SM, Shen K. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res. 2001;888:75-82.
46. Fontana F, Bernardi P, Pich EM, et al. Opioid peptide modulation of circulatory and endocrine response to mental stress in humans. Peptides. 1997;18:169-175.
47. Weinstein IJ, Hough LB, Gogas KR. Cross-tolerance and cross-sensitization between morphine analgesia and naloxone-sensitive and cimetidine-sensitive stress-induced analgesia. J Pharm Exp Therap. 1988; 244:253-258.
48. Westbrook RF, Greeley JD. Some effects of the opioid antagonist, naloxone, upon the rat's reactions to a heat stressor. Q J Psychol B. 1990;42: 1-40.
49. Singewald N, Philippu A. Release of neurotransmitters in the locus coeruleus. Progr Neurobiol. 1998;56:237-267.
50. Von Knorring L, Almay BGL, Johansson F, et al. Pain perception and endorphin levels in cerebrospinal fluid. Pain. 1978;5:359-365.
51. Turk DC, Rudy TE. Neglected factors in chronic pain treatment outcome studies: referral patterns, failure to enter treatment, and attrition. Pain. 1990;43:7-25.
52. Atkinson JH, Kremer EF, Risch SC, et al. Plasma measures of beta-endorphin/beta-lipotropin-like immunoreactivity in chronic pain syndrome and psychiatric subjects. Psychiatry Res. 1983;9:319-327.
53. Harrison LM, Kastin AJ, Zadina JE. Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. Peptides. 1999; 19:1603-1630.
54. Poudervigne MS, O'Connor PJ, Pasley JD. Lack of both sex differences and influence of resting blood pressure on muscle pain intensity. Clin J Pain. 2002;18:386-393.
55. Grevert P, Goldstein A. Endorphins: naloxone fails to alter experimental pain or mood in humans. Science. 1978;199:1093-1095.
56. Posner J, Burke CA. The effects of naloxone on opiate and placebo analgesia in healthy volunteers. Psychopharm. 1985;87:468-472.
57. Anderson WS, Sheth RN, Bencherif B, et al. Naloxone increases pain induced by topical capsaicin in healthy human volunteers. Pain. 2002;99: 207-216.
58. Frid M, Singer G, Rana C. Interactions between personal expectations and naloxone: effects on tolerance to ischemic pain. Psychopharm. 1979;65: 225-231.
59. Schull J, Kaplan H, O'Brien CP. Naloxone can alter experimental pain and mood in humans. Physiol Psych. 1981;9:245-250.
60. Willer JC, Dehen H, Cambier J. Stress-induced analgesia in humans: endogenous opioids and naloxone-reversible pain reflexes. Science. 1981; 212:689-691.
61. Willer JC, Ernst M. Diazepam reduces stress-induced analgesia in humans. Brain Res. 1986;362:398-402.